GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
45.51
+0.30 (+0.66%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close45.21
Open45.40
Bid0.00 x 2200
Ask0.00 x 1800
Day's Range45.27 - 45.57
52 Week Range36.87 - 46.01
Volume2,550,081
Avg. Volume2,647,869
Market Cap114.287B
Beta (3Y Monthly)0.37
PE Ratio (TTM)45.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.96 (4.30%)
Ex-Dividend Date2019-11-14
1y Target EstN/A
  • The GlaxoSmithKline (LON:GSK) Share Price Is Up 27% And Shareholders Are Holding On
    Simply Wall St.

    The GlaxoSmithKline (LON:GSK) Share Price Is Up 27% And Shareholders Are Holding On

    Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...

  • Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
    Zacks

    Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

    The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.

  • AstraZeneca's Lynparza Gets China Nod in First-Line Setting
    Zacks

    AstraZeneca's Lynparza Gets China Nod in First-Line Setting

    AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.

  • Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
    Zacks

    Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV

    Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.

  • Hedge Funds Are Warming Up To GlaxoSmithKline plc  (GSK)
    Insider Monkey

    Hedge Funds Are Warming Up To GlaxoSmithKline plc (GSK)

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • Are You Looking for a Top Momentum Pick? Why GlaxoSmithKline (GSK) is a Great Choice
    Zacks

    Are You Looking for a Top Momentum Pick? Why GlaxoSmithKline (GSK) is a Great Choice

    Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
    Zacks

    Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD

    The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.

  • Reuters

    GSK seeks FDA approval for investigational HIV treatment

    GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults. Fostemsavir is being developed for use in combination with other antiretroviral agents in adults who have been previously taken treatments for HIV and have developed resistance to the drugs due to various factors. Antiretroviral medicines that can effectively suppress HIV have been instrumental in decreasing disease progression, HIV transmission, and AIDS-related deaths, but because of HIV's ability to constantly change, some individuals can develop viral resistance, causing their treatment regimens to fail.

  • Is GlaxoSmithKline (GSK) a Great Value Stock Right Now?
    Zacks

    Is GlaxoSmithKline (GSK) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Bristol-Myers' Reblozyl to be Reviewed by FDA Committee
    Zacks

    Bristol-Myers' Reblozyl to be Reviewed by FDA Committee

    Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.

  • Pfizer Stock Is A Top Pharma Company — But Should You Buy It?
    Investor's Business Daily

    Pfizer Stock Is A Top Pharma Company — But Should You Buy It?

    Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • Epizyme Announces FDA Committee Review of Tazemetostat NDA
    Zacks

    Epizyme Announces FDA Committee Review of Tazemetostat NDA

    Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.

  • Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer
    Zacks

    Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

    Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.

  • Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
    Zacks

    Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

    Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

  • [video]Glaxosmithkline Could Rise 20% From Here
    TheStreet.com

    [video]Glaxosmithkline Could Rise 20% From Here

    Glaxosmithkline Plc has broken out on the upside on our Point and Figure charts. Let's check out our usual set of charts before we focus on the Point and Figure breakout. In the daily bar chart of GSK, below, we can see that prices broke out on the upside in October after an eight-month sideways consolidation pattern.

  • GuruFocus.com

    Safety Could Determine Who Wins the Next-Generation HBV Vaccine Market

    The winner of the next-generation hepatitis B vaccine market could largely be determined by upcoming safety data between Sci-B-Vac and Heplisav-B Continue reading...

  • The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments
    Zacks

    The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments

    The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments

  • Top Analyst Reports for Apple, Comcast & NVIDIA
    Zacks

    Top Analyst Reports for Apple, Comcast & NVIDIA

    Top Analyst Reports for Apple, Comcast & NVIDIA

  • India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo
    Bloomberg

    India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo

    (Bloomberg) -- Terms of Trade is a daily newsletter that untangles a world embroiled in trade wars. Sign up here. India is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in the South Asian nation in a bid to capitalize from the trade war between China and the U.S., according to a document seen by Bloomberg.The government proposes to provide the manufacturers land to set up a factory along with power, water and road access, according to draft of the document prepared by the Department for Promotion of Industry and Internal Trade and Invest India. Other companies that officials will reach out to include Eli Lilly & Co., South Korea’s Hanwha Chemical Corp., and Taiwan’s Hon Hai Precision Industry Co.While the trade war has benefited countries such as Vietnam and Malaysia, rigid land acquisition rules and labor laws have prompted investors to largely ignore India when looking for alternatives to China. The latest proposal may reduce red tape, and set the nation, which expanded at the slowest pace in six years last quarter, on a path to double its gross domestic product to $5 trillion by 2025 -- a goal set Prime Minister Narendra Modi.“While in the initial leg of relocation we have seen companies moving to Vietnam, I don’t think it is too late for India to start making an effort,” said Sonal Varma, chief economist for India and Asia-ex Japan at Nomura Holdings Inc. in Singapore. “India offers a unique advantage of being a huge domestic market too, so it is definitely an opportunity for the government to attract investment.”Under the plan, the government will create a land bank for ready-to-move-in industrial clusters, offer investment and location-based incentives and rationalize anti-dumping duties. The proposal includes incentives for plug-in and hybrid vehicles, fuel efficiency and carbon taxation. For the electronics and telecom sector, flexible employment, manufacturing-related incentives linked to investments and value addition have been sought.The country has made progress, rising 37 spots since 2017 in the World Bank’s ranking for ease of doing business, but it still comes in at 63rd, trailing not only China, but also Rwanda and Kosovo. At present, investors keen on setting up a factory need to acquire land on their own which, in some cases, involves a time consuming process of negotiating with small plot owners to part with their holding.The Prime Minister’s Office is considering the proposal and a decision is expected soon. An email sent to the spokeswoman at the commerce and industry ministry wasn’t immediately answered.Asia’s third-largest economy expanded 5% in the June quarter, with slew of data pointing to weaker economic activity.Getting investment inflows and boosting exports is therefore high on economic agenda of the government. It has already slashed corporate tax rate, making it competitive with rest of Asia, and has relaxed foreign investment rules to attract fund inflows in the country.(Updates with economist’s comment in fourth paragraph)To contact the reporter on this story: Shruti Srivastava in New Delhi at ssrivastav74@bloomberg.netTo contact the editors responsible for this story: Arijit Ghosh at aghosh@bloomberg.net, Unni KrishnanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
    Zacks

    Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies

    Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.

  • Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs
    Zacks

    Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

    Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

  • Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
    Zacks

    Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

  • AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
    Zacks

    AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

    The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

  • Should Value Investors Buy GlaxoSmithKline (GSK) Stock?
    Zacks

    Should Value Investors Buy GlaxoSmithKline (GSK) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.